Abstract
Gamma-amino butyric acid (GABA), the major inhibitory neurotransmitter in the mammalian central nervous system, plays a key role in the regulation of neuronal transmission throughout the brain, affecting numerous physiological and psychological processes. Changes in GABA levels provoke disbalance between excitatory and inhibitory signals, and are involved in the development of numerous neuropsychiatric disorders. GABA exerts its effects via ionotropic (GABAA) and metabotropic (GABAB) receptors. Both types of receptors are targeted by many clinically important drugs that affect GABAergic function and are widely used in the treatment of anxiety disorder, epilepsy, insomnia, spasticity, aggressive behaviour, and other pathophysiological conditions and diseases. Of particular importance are drugs that modulate GABAA receptor complex, such as benzodiazepines, barbiturates, neuroactive steroids, intravenous and inhalational anesthetics, and ethanol. Molecular interactions and subsequent pharmacological effects induced by drugs acting at GABAA receptors are extremely complex due to structural heterogeneity of GABAA receptors and existence of numerous allosterically interconnected binding sites and various chemically distinct ligands that are able to bound to them. There is a growing interest in the development and application of subtype-selective drugs that will achieve specific therapeutic benefits without undesirable side effects. The aim of this review is to briefly summarize the key pharmacological properties of GABA receptors, and to present selected novel findings with the potential to open new perspectives in the development of more effective therapeutic strategies.
Keywords: GABA, GABA receptor pharmacology, benzodiazepines, neurosteroids.
Current Pharmaceutical Design
Title:GABA Receptors: Pharmacological Potential and Pitfalls
Volume: 21 Issue: 34
Author(s): Maja Jazvinscak Jembrek and Josipa Vlainic
Affiliation:
Keywords: GABA, GABA receptor pharmacology, benzodiazepines, neurosteroids.
Abstract: Gamma-amino butyric acid (GABA), the major inhibitory neurotransmitter in the mammalian central nervous system, plays a key role in the regulation of neuronal transmission throughout the brain, affecting numerous physiological and psychological processes. Changes in GABA levels provoke disbalance between excitatory and inhibitory signals, and are involved in the development of numerous neuropsychiatric disorders. GABA exerts its effects via ionotropic (GABAA) and metabotropic (GABAB) receptors. Both types of receptors are targeted by many clinically important drugs that affect GABAergic function and are widely used in the treatment of anxiety disorder, epilepsy, insomnia, spasticity, aggressive behaviour, and other pathophysiological conditions and diseases. Of particular importance are drugs that modulate GABAA receptor complex, such as benzodiazepines, barbiturates, neuroactive steroids, intravenous and inhalational anesthetics, and ethanol. Molecular interactions and subsequent pharmacological effects induced by drugs acting at GABAA receptors are extremely complex due to structural heterogeneity of GABAA receptors and existence of numerous allosterically interconnected binding sites and various chemically distinct ligands that are able to bound to them. There is a growing interest in the development and application of subtype-selective drugs that will achieve specific therapeutic benefits without undesirable side effects. The aim of this review is to briefly summarize the key pharmacological properties of GABA receptors, and to present selected novel findings with the potential to open new perspectives in the development of more effective therapeutic strategies.
Export Options
About this article
Cite this article as:
Jembrek Jazvinscak Maja and Vlainic Josipa, GABA Receptors: Pharmacological Potential and Pitfalls, Current Pharmaceutical Design 2015; 21 (34) . https://dx.doi.org/10.2174/1381612821666150914121624
DOI https://dx.doi.org/10.2174/1381612821666150914121624 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
Innovative delivery systems and formulations for the management of diseases affecting the skin and skin appendages
Skin and skin appendage diseases have high incidence and can highly impact the quality of life. Such diseases include pigmentation disorders, such as melasma, vitiligo and post-inflammatory hyperpigmentation, infectious diseases caused by fungi, viruses, bacteria and parasites, inflammatory diseases such as acne, dermatitis, rosacea, and psoriasis, as well as skin ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AMPA Receptor Antagonists as Potential Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology
Current Drug Delivery The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Preface
Current Neuropharmacology Rethinking the Excitotoxic Ionic Milieu:The Emerging Role of Zn 2+ in Ischemic Neuronal Injury
Current Molecular Medicine The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design New Insights in Prolactin Releasing Peptide (Prrp) in the Brain
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease
Current Pharmaceutical Design Mechanism of <i>Polygala-Acorus</i> in Treating Autism Spectrum Disorder Based on Network Pharmacology and Molecular Docking
Current Computer-Aided Drug Design Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry